ALBANY MOLECULAR RESH INC (AMRI) Stock Price & Overview

NASDAQ:AMRI • US0124231095

21.74
0 (0%)
At close: Aug 31, 2017
21.74
0 (0%)
After Hours: 8/31/2017, 8:15:11 PM

The current stock price of AMRI is 21.74 null. Today AMRI is down by 0%. In the past month the price increased by 0.23%. In the past year, price increased by 48.4%.

AMRI Key Statistics

52-Week Range13.01 - 22.17
Current AMRI stock price positioned within its 52-week range.
1-Month Range21.65 - 21.78
Current AMRI stock price positioned within its 1-month range.
Market Cap
937.429M
P/E
N/A
Fwd P/E
23.89
EPS (TTM)
-1.42
Dividend Yield
N/A

AMRI Stock Performance

Today
0%
1 Week
+0.09%
1 Month
+0.23%
3 Months
+7.78%
Longer-term
6 Months +50.35%
1 Year +48.40%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

AMRI Stock Chart

ALBANY MOLECULAR RESH INC / AMRI Daily stock chart

AMRI Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to AMRI. When comparing the yearly performance of all stocks, AMRI is one of the better performing stocks in the market, outperforming 87.04% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
AMRI Full Technical Analysis Report

AMRI Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AMRI. AMRI may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AMRI Full Fundamental Analysis Report

AMRI Earnings

Next Earnings DateN/A
Last Earnings DateN/A
AMRI Earnings History

AMRI Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next Y149.73%
Revenue Next YearN/A
AMRI Forecast & Estimates

AMRI Financial Highlights

Over the last trailing twelve months AMRI reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS decreased by -46.39% compared to the year before.


Income Statements
Revenue(TTM)680.82M
Net Income(TTM)-59.78M
Industry RankSector Rank
PM (TTM) -8.78%
ROA -4.81%
ROE -18.86%
Debt/Equity 0.62
Chartmill High Growth Momentum
EPS Q2Q%60.66%
Sales Q2Q%43.14%
EPS 1Y (TTM)-46.39%
Revenue 1Y (TTM)48.85%
AMRI financials

AMRI Ownership

Ownership
Inst Owners0%
Shares43.12M
Float37.08M
Ins Owners22.61%
Short Float %N/A
Short RatioN/A
AMRI Ownership

About AMRI

Company Profile

Albany Molecular Research is an integrated provider of drug discovery and development, chemistry research and manufacturing services. They offer services traditionally provided by chemistry divisions within pharmaceutical and biotechnology companies, including drug discovery, medicinal chemistry, chemical development, analytical chemistry services and small-scale and pilot-plant manufacturing. Recently, they expanded their service offerings to include commercial manufacturing through their strategic relationship with and investment in Organichem Corporation.

Company Info

ALBANY MOLECULAR RESH INC

26 CORPORATE CIRCLE

ALBANY NY 12212

CEO: William S. Marth

Phone: 518-512-2000

ALBANY MOLECULAR RESH INC / AMRI FAQ

Can you describe the business of ALBANY MOLECULAR RESH INC?

Albany Molecular Research is an integrated provider of drug discovery and development, chemistry research and manufacturing services. They offer services traditionally provided by chemistry divisions within pharmaceutical and biotechnology companies, including drug discovery, medicinal chemistry, chemical development, analytical chemistry services and small-scale and pilot-plant manufacturing. Recently, they expanded their service offerings to include commercial manufacturing through their strategic relationship with and investment in Organichem Corporation.


What is the stock price of ALBANY MOLECULAR RESH INC today?

The current stock price of AMRI is 21.74 null.


What is the dividend status of ALBANY MOLECULAR RESH INC?

AMRI does not pay a dividend.


What is the ChartMill technical and fundamental rating of AMRI stock?

AMRI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the Price/Earnings (PE) ratio of ALBANY MOLECULAR RESH INC (AMRI)?

ALBANY MOLECULAR RESH INC (AMRI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.42).